J. Exp. Med.
© The Rockefeller University Press
0022-1007/97/08/695/10 $2.00
Volume 186, Number 5, August 29, 1997 695-704

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

By Michel P.M. Vierboom,^* Hans W. Nijman,^* Rienk Offringa,^* Ellen I.H. van der Voort,^* Thorbald van Hall,^* Lambert van den Broek,^§ Gert Jan Fleuren,^§ Peter Kenemans, W. Martin Kast, and Cornelis J.M. Melief^*

From the ^* Department of Immunohematology and Blood Bank, University Hospital Leiden, 2300 RC Leiden, the Netherlands;  Department of Obstetrics and Gynaecology, Free University Hospital, 1007 MB Amsterdam, The Netherlands; ^§ Department of Pathology, University Hospital Leiden, 2300 RC Leiden, The Netherlands; and  Cancer Immunology Program, Cardinal Bernadin Cancer Center, Loyola University of Chicago, Maywood, Illinois 60153

The tumor suppressor protein p53 is overexpressed in close to 50% of all human malignancies. The p53 protein is therefore an attractive target for immunotherapy. Cytotoxic T lymphocytes (CTLs) recognizing a murine wild-type p53 peptide, presented by the major histocompatibility complex class I molecule H-2K^b, were generated by immunizing p53 gene deficient (p53 /) C57BL/6 mice with syngeneic p53-overexpressing tumor cells. Adoptive transfer of these CTLs into tumor-bearing p53 +/+ nude mice caused complete and permanent tumor eradication. Importantly, this occurred in the absence of any demonstrable damage to normal tissue. When transferred into p53 +/+ immunocompetent C57BL/6 mice, the CTLs persisted for weeks in the absence of immunopathology and were capable of preventing tumor outgrowth. Wild-type p53-specific CTLs can apparently discriminate between p53-overexpressing tumor cells and normal tissue, indicating that widely expressed autologous molecules such as p53 can serve as a target for CTL-mediated immunotherapy of tumors.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Barve, M., Bender, J., Senzer, N., Cunningham, C., Greco, F. A., McCune, D., Steis, R., Khong, H., Richards, D., Stephenson, J., Ganesa, P., Nemunaitis, J., Ishioka, G., Pappen, B., Nemunaitis, M., Morse, M., Mills, B., Maples, P. B., Sherman, J., Nemunaitis, J. J. (2008). Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer. JCO 26: 4418-4425 [Abstract] [Full Text]  
• Lauwen, M. M., Zwaveling, S., de Quartel, L., Ferreira Mota, S. C., Grashorn, J. A.C., Melief, C. J.M., van der Burg, S. H., Offringa, R. (2008). Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen. Cancer Res. 68: 893-900 [Abstract] [Full Text]  
• Bos, R., van Duikeren, S., van Hall, T., Lauwen, M. M., Parrington, M., Berinstein, N. L., McNeil, B., Melief, C. J. M., Verbeek, J. S., van der Burg, S. H., Offringa, R. (2007). Characterization of Antigen-Specific Immune Responses Induced by Canarypox Virus Vaccines. J. Immunol. 179: 6115-6122 [Abstract] [Full Text]  
• Weinhold, M., Sommermeyer, D., Uckert, W., Blankenstein, T. (2007). Dual T Cell Receptor Expressing CD8+ T Cells with Tumor- and Self-Specificity Can Inhibit Tumor Growth without Causing Severe Autoimmunity. J. Immunol. 179: 5534-5542 [Abstract] [Full Text]  
• Wysocki, P. J., Kwiatkowska, E. P., Kazimierczak, U., Suchorska, W., Kowalczyk, D. W., Mackiewicz, A. (2006). Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice.. Clin. Cancer Res. 12: 4095-4102 [Abstract] [Full Text]  
• Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., Menander, K., Chada, S., Gabrilovich, D. I. (2006). Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer. Clin. Cancer Res. 12: 878-887 [Abstract] [Full Text]  
• Madurga, S., Belda, I., Llora, X., Giralt, E. (2005). Design of enhanced agonists through the use of a new virtual screening method: Application to peptides that bind class I major histocompatibility complex (MHC) molecules. Protein Sci. 14: 2069-2079 [Abstract] [Full Text]  
• Bendle, G. M., Holler, A., Pang, L.-K., Hsu, S., Krampera, M., Simpson, E., Stauss, H. J. (2004). Induction of Unresponsiveness Limits Tumor Protection by Adoptively Transferred MDM2-Specific Cytotoxic T Lymphocytes. Cancer Res. 64: 8052-8056 [Abstract] [Full Text]  
• Daftarian, P., Song, G.-Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., Ellenhorn, J. D. I. (2004). Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors. Cancer Res. 64: 5407-5414 [Abstract] [Full Text]  
• Lomas, M., Liauw, W., Packham, D., Williams, K., Kelleher, A., Zaunders, J., Ward, R. (2004). Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Ann Oncol 15: 324-329 [Abstract] [Full Text]  
• Ramirez, F., Ghani, Y., Stauss, H. (2004). Incomplete tolerance to the tumour-associated antigen MDM2. Int Immunol 16: 327-334 [Abstract] [Full Text]  
• Li, J., Li, W., Liang, S., Cai, D., Kieny, M. P., Jacob, L., Linnenbach, A., Abramczuk, J. W., Bender, H., Sproesser, K., Swoboda, R., Somasundaram, R., Guerry, D., Herlyn, D. (2003). Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice. J. Immunol. 171: 2922-2929 [Abstract] [Full Text]  
• Espenschied, J., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., Ellenhorn, J. D. I. (2003). CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model. J. Immunol. 170: 3401-3407 [Abstract] [Full Text]  
• Zwaveling, S., Vierboom, M. P. M., Ferreira Mota, S. C., Hendriks, J. A., Ooms, M. E., Sutmuller, R. P. M., Franken, K. L. M. C., Nijman, H. W., Ossendorp, F., van der Burg, S. H., Offringa, R., Melief, C. J. M. (2002). Antitumor Efficacy of Wild-Type p53-specific CD4+ T-Helper Cells. Cancer Res. 62: 6187-6193 [Abstract] [Full Text]  
• Gatza, E., Okada, C. Y. (2002). Tumor Cell Lysate-Pulsed Dendritic Cells Are More Effective Than TCR Id Protein Vaccines for Active Immunotherapy of T Cell Lymphoma. J. Immunol. 169: 5227-5235 [Abstract] [Full Text]  
• Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., Melief, C. J. M. (2002). Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides. J. Immunol. 169: 350-358 [Abstract] [Full Text]  
• Konopitzky, R., Konig, U., Meyer, R. G., Sommergruber, W., Wolfel, T., Schweighoffer, T. (2002). Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the Novel Overexpressed Tumor Antigen Calcium-Activated Chloride Channel 2. J. Immunol. 169: 540-547 [Abstract] [Full Text]  
• Hoffmann, T. K., Donnenberg, A. D., Finkelstein, S. D., Donnenberg, V. S., Friebe-Hoffmann, U., Myers, E. N., Appella, E., DeLeo, A. B., Whiteside, T. L. (2002). Frequencies of Tetramer+ T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in the Circulation of Patients with Head and Neck Cancer. Cancer Res. 62: 3521-3529 [Abstract] [Full Text]  
• van der Burg, S. H., Menon, A. G, Redeker, A., Bonnet, M.-C., Drijfhout, J. W., Tollenaar, R. A. E. M., van de Velde, C. J. H., Moingeon, P., Kuppen, P. J. K., Offringa, R., Melief, C. J. M. (2002). Induction of p53-specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine. Clin. Cancer Res. 8: 1019-1027 [Abstract] [Full Text]  
• Berinstein, N. L. (2002). Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review. JCO 20: 2197-2207 [Abstract] [Full Text]  
• Passoni, L., Scardino, A., Bertazzoli, C., Gallo, B., Coluccia, A. M. L., Lemonnier, F. A., Kosmatopoulos, K., Gambacorti-Passerini, C. (2002). ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99: 2100-2106 [Abstract] [Full Text]  
• Cordaro, T. A., de Visser, K. E., Tirion, F. H., Schumacher, T. N. M., Kruisbeek, A. M. (2002). Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?. J. Immunol. 168: 651-660 [Abstract] [Full Text]  
• Armstrong, A C, Hawkins, R E (2001). Vaccines in oncology: background and clinical potential. Br. J. Radiol. 74: 991-1002 [Abstract] [Full Text]  
• Tatsumi, T., Takehara, T., Kanto, T., Miyagi, T., Kuzushita, N., Sugimoto, Y., Jinushi, M., Kasahara, A., Sasaki, Y., Hori, M., Hayashi, N. (2001). Administration of Interleukin-12 Enhances the Therapeutic Efficacy of Dendritic Cell-based Tumor Vaccines in Mouse Hepatocellular Carcinoma. Cancer Res. 61: 7563-7567 [Abstract] [Full Text]  
• Meyer zum Buschenfelde, C., Metzger, J., Hermann, C., Nicklisch, N., Peschel, C., Bernhard, H. (2001). The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells. J. Immunol. 167: 1712-1719 [Abstract] [Full Text]  
• Keogh, E., Fikes, J., Southwood, S., Celis, E., Chesnut, R., Sette, A. (2001). Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity. J. Immunol. 167: 787-796 [Abstract] [Full Text]  
• Helmich, B. K., Dutton, R. W. (2001). The Role of Adoptively Transferred CD8 T Cells and Host Cells in the Control of the Growth of the EG7 Thymoma: Factors That Determine the Relative Effectiveness and Homing Properties of Tc1 and Tc2 Effectors. J. Immunol. 166: 6500-6508 [Abstract] [Full Text]  
• Eck, S. C., Turka, L. A. (2001). Adoptive Transfer Enables Tumor Rejection Targeted against a Self-Antigen without the Induction of Autoimmunity. Cancer Res. 61: 3077-3083 [Abstract] [Full Text]  
• Ohlen, C., Kalos, M., Hong, D. J., Shur, A. C., Greenberg, P. D. (2001). Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen. J. Immunol. 166: 2863-2870 [Abstract] [Full Text]  
• Kessler, J. H., Beekman, N. J., Bres-Vloemans, S. A., Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M., Vissers, D. C.J., ten Bosch, G. J.A., Kester, M. G.D., Sijts, A., Drijfhout, J. W., Ossendorp, F., Offringa, R., Melief, C. J.M. (2001). Efficient Identification of Novel HLA-A*0201-presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen PRAME by Proteasome-mediated Digestion Analysis. J. Exp. Med. 193: 73-88 [Abstract] [Full Text]  
• Hoffmann, T. K., Nakano, K., Elder, E. M., Dworacki, G., Finkelstein, S. D., Appella, E., Whiteside, T. L., DeLeo, A. B. (2000). Generation of T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in Cancer Patients: Implications for Immunoselection of Epitope Loss Variants. J. Immunol. 165: 5938-5944 [Abstract] [Full Text]  
• Vierboom, M. P. M., Zwaveling, S., Bos, G. M. J., Ooms, M., Krietemeijer, G. M., Melief, C. J. M., Offringa, R. (2000). High Steady-State Levels of p53 Are Not a Prerequisite for Tumor Eradication by Wild-Type p53-specific Cytotoxic T Lymphocytes. Cancer Res. 60: 5508-5513 [Abstract] [Full Text]  
• Herr, W., Ranieri, E., Olson, W., Zarour, H., Gesualdo, L., Storkus, W. J. (2000). Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses. Blood 96: 1857-1864 [Abstract] [Full Text]  
• van Hall, T., van Bergen, J., van Veelen, P. A., Kraakman, M., Heukamp, L. C., Koning, F., Melief, C. J. M., Ossendorp, F., Offringa, R. (2000). Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin. J. Immunol. 165: 869-877 [Abstract] [Full Text]  
• Fedoseyeva, E. V., Boisgerault, F., Anosova, N. G., Wollish, W. S., Arlotta, P., Jensen, P. E., Ono, S. J., Benichou, G. (2000). CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice. J. Immunol. 164: 5641-5651 [Abstract] [Full Text]  
• Eura, M., Chikamatsu, K., Katsura, F., Obata, A., Sobao, Y., Takiguchi, M., Song, Y., Appella, E., Whiteside, T. L., DeLeo, A. B. (2000). A Wild-type Sequence p53 Peptide Presented by HLA-A24 Induces Cytotoxic T Lymphocytes that Recognize Squamous Cell Carcinomas of the Head and Neck. Clin. Cancer Res. 6: 979-986 [Abstract] [Full Text]  
• Liu, X., Peralta, E. A., Ellenhorn, J. D. I., Diamond, D. J. (2000). Targeting of Human p53-overexpressing Tumor Cells by an HLA A*0201-restricted Murine T-Cell Receptor Expressed in Jurkat T Cells. Cancer Res. 60: 693-701 [Abstract] [Full Text]  
• Nolan, K. F., Yun, C.-O., Akamatsu, Y., Murphy, J. C., Leung, S.-O., Beecham, E. J., Junghans, R. P. (1999). Bypassing Immunization: Optimized Design of ""Designer T Cells"" against Carcinoembryonic Antigen (CEA)-expressing Tumors, and Lack of Suppression by Soluble CEA. Clin. Cancer Res. 5: 3928-3941 [Abstract] [Full Text]  
• Papadopoulos, K. P., Hesdorffer, C. S., Suciu-Foca, N., Hibshoosh, H., Harris, P. E. (1999). Wild-Type p53 Epitope Naturally Processed and Presented by an HLA-B Haplotype on Human Breast Carcinoma Cells. Clin. Cancer Res. 5: 2089-2093 [Abstract] [Full Text]  
• Vollmer, C. M. Jr., Eilber, F. C., Butterfield, L. H., Ribas, A., Dissette, V. B., Koh, A., Montejo, L. D., Lee, M. C., Andrews, K. J., McBride, W. H., Glaspy, J. A., Economou, J. S. (1999). {{alpha}}-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma. Cancer Res. 59: 3064-3067 [Abstract] [Full Text]  
• Tempero, R. M., VanLith, M. L., Morikane, K., Rowse, G. J., Gendler, S. J., Hollingsworth, M. A. (1998). CD4+ Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice. J. Immunol. 161: 5500-5506 [Abstract] [Full Text]  
• Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Haussler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P.-M., Sherman, L. A. (1998). The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope. J. Exp. Med. 188: 1017-1028 [Abstract] [Full Text]  
• Fields, R. C., Shimizu, K., Mule, J. J. (1998). Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95: 9482-9487 [Abstract] [Full Text]  
• Toes, R. E. M., Hoeben, R. C., van der Voort, E. I. H., Ressing, M. E., van der Eb, A. J., Melief, C. J. M., Offringa, R. (1997). Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl. Acad. Sci. USA 94: 14660-14665 [Abstract] [Full Text]  
• Asavaroengchai, W., Kotera, Y., Mule, J. J. (2002). Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA 99: 931-936 [Abstract] [Full Text]  
• van Vlijmen, B. J.M., Gerritsen, G., Franken, A. L., Boesten, L. S.M., Kockx, M. M., Gijbels, M. J., Vierboom, M. P., van Eck, M., van de Water, B., van Berkel, T. J.C., Havekes, L. M. (2001). Macrophage p53 Deficiency Leads to Enhanced Atherosclerosis in APOE*3-Leiden Transgenic Mice. Circ. Res. 88: 780-786 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS